Stay updated on Alirocumab in Dialysis Patients Clinical Trial
Sign up to get notified when there's something new on the Alirocumab in Dialysis Patients Clinical Trial page.

Latest updates to the Alirocumab in Dialysis Patients Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe study record history now shows a new revision labeled v3.6.4, replacing the previous v3.6.3. This indicates a software or documentation update to the history page.SummaryDifference0.1%

- Check18 days agoNo Change Detected
- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedThe Record History gains a new revision entry v3.6.3, replacing the previous v3.6.2 to reflect the latest version update of the study record.SummaryDifference0.1%

- Check39 days agoChange DetectedThe Record History shows a new revision tag (Revision: v3.6.2), indicating an administrative update to the ClinicalTrials.gov record. It does not alter any study data or visible content, but updates the version history for auditing.SummaryDifference0.1%

- Check54 days agoChange DetectedThe study record page now includes 'Check who can join' and 'Find Contact Information' links; the revision history also shows a new site release (Revision: v3.6.0) replacing the prior (v3.5.5).SummaryDifference0.5%

- Check61 days agoChange DetectedThe record history includes a new revision entry labeled v3.5.5. The previous revision v3.5.4 has been removed from the listing, indicating an update to the history log rather than substantive changes to the study record.SummaryDifference0.1%

- Check68 days agoChange DetectedA new version adds Study Status and QC details, and expands the record to expose major study sections such as Adverse Events, Outcome Measures, Baseline Characteristics, and Participant Flow.SummaryDifference2%

Stay in the know with updates to Alirocumab in Dialysis Patients Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Alirocumab in Dialysis Patients Clinical Trial page.